Assess whether to resubmit, meet, or pause the program (8bde97)

SITUATION Pediatric-plan strategist at a 505(b)(2) program relying on literature plus a bridging study is reviewing disproportionate reporting signal workbook after a competitor label that just got a narrower indication. The question on that extract is whether to resubmit, meet, or pause the program. The packet does not yet prove To resubmit, meet, versus Pause the program.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose To resubmit, meet, / Pause the program using disproportionate reporting signal workbook after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. The population in disproportionate reporting signal workbook is the one a competitor label that just got a narrower indication named, so To resubmit, meet, follows for this Clinical and Evidence Strategy file. 2. The population in disproportionate reporting signal workbook is adjacent only to a competitor label that just got a narrower indication; Pause the program is the honest Pharma & Life Sciences call. 3. A 505(b)(2) program relying on literature plus a bridging study already contained a competitor label that just got a narrower indication before disproportionate reporting signal workbook arrived; no new Clinical and Evidence Strategy path. 4. Provenance on disproportionate reporting signal workbook after a competitor label that just got a narrower indication is broken; do not pick To resubmit, meet, or Pause the program yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a competitor label that just got a narrower indication. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a competitor label that just got a narrower indication and write the one fact that would move to resubmit, meet, or for pediatric-plan strategist.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study.